Novel Formulation Bases and Pre-clinical Trial Results for Rx Drug Candidates

CanaQuest Medical is a clinical-stage life sciences company focused on the drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors.

CanaQuest is collaborating with multiple Canadian universities including a Western University team led by Dr. Steven Laviolette, who has decades of research experience focused on novel pharmacotherapies to treat neurological conditions, such as anxiety, depression, schizophrenia, and Post Traumatic Stress Disorder “PTSD”, including addiction.

Dr. Laviolette’s team has made two amazing drug candidate discoveries, Rx CQ-001 (CBD molecules + formula) and Rx CQ-002 (THC molecules + formula), for treating mental ailments. Pre-clinical trials completed – setting the stage for pre-approved clinical trials.

To learn more about our value proposition and our pre-approved clinical trials, view our Corporate Presentation by clicking the thumbnail graphic further down.

2021 Global Excellence Awards
Best Medical Cannabis and Botanical Oils Product Development Company, 2021 – North America

Awarded by Global Health & Pharma, UK

Corporate Presentation

Our corporate introduction document provides a comprehensive summary of CanaQuest today and its many opportunities for the future.

Click picture above to see the full presentation.

Product Formulations

Drug Candidate Formulations

CanaQuest is primed to realize the infinite potential of targeted therapeutics within the endocannabinoid system and specific brain receptors to mediated signaling pathways.

CQ-001, Drug Candidate – Epilepsy

(CBD molecules + formula)

Clinical-trial stage

Supports anxiety, depression, schizophrenia, PTSD and addiction

CQ-002, Drug Candidate – Safer alternative

(THC molecules + formula)

Clinical-trial stage

Supports mental health: safer alternative to THC by itself

CQ-003, Drug Candidate – Pain

(CBD molecules + formula)

In development

To support inflammation & pain

CQ-004, Drug Candidate – Alzheimer’s

(THC + CBD molecules + formula)

In development

To support mental health

Formulation Bases for Drug Candidates







Chronic Pain



Our vision is to be a global leader in the formulation and development of medicine derived from cannabinoids and other botanical-based molecules.

Company Information


View All News
804, 2021

CanaQuest Medical Corp Appoints Investor Relations and PR Veteran Rob Rinderman as its New Director of Communications

April 8th, 2021|

TORONTO, ON / April 7, 2021 -- CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), an award-winning Life Science/Pharmaceutical company developing health and wellness products combining cannabinoid molecules with pharmaceutical-grade botanical compounds, today announced that Rob Rinderman [...]